<DOC>
	<DOCNO>NCT02294994</DOCNO>
	<brief_summary>The aim study investigate efficacy safety different dose GPIIb/IIIa inhibitor ( tirofiban ) interventional treatment complex coronary artery disease , include bifurcation lesion , leave main lesion , multiple vessel disease , intracoronary thrombus , SYNTAX score &gt; 26 , chronic total occlusion disease . The primary endpoint all-cause mortality . Secondary endpoint incidence major bleed rate site access complication .</brief_summary>
	<brief_title>Efficacy Safety Different Dose Tirofiban Interventional Treatment Complex Coronary Artery Disease</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Tirofiban</mesh_term>
	<criteria>Patients recruit undergoing PCI plan placement intracoronary stent Including patient unstable angina pectoris , acute coronary syndrome NSTEMI Experienced ischaemic pain rest Lasting 10 minute occur within 7 day enrollment As well one following : ECG change : New presumably new STsegment depression great equal 0.1 mV ( 1 mm ) , transient ( &lt; 30 minute ) STsegment elevation great equal 0.1 mV ( 1 mm ) least 2 contiguous lead Abnormal cardiac enzyme within 24 hour enrollment , define elevated Troponin I define elevated Troponin I ( normal reference Highrisk angiographic feature : lesion/anatomy related bifurcation lesion , leave main lesion , multiple vessel disease , intracoronary thrombus , SYNTAX score &gt; 26 chronic total occlusion disease . Increased bleed risk : ischaemic stroke within last year previous haemorrhagic stroke , tumour intracranial aneurysm ; Recent ( &lt; 1 month ) trauma major surgery ( include bypass surgery ) ; Active bleeding Unexplained clinically significant bleeding , thrombocytopenia ( platelet count &lt; 100 x 109/L ) history thrombocytopenia GP IIb/IIIa , heparin enoxaparin therapy Angina secondary cause severe uncontrolled hypertension ( systolic blood pressure &gt; 180 mm Hg despite treatment ) Valvular disease , congenital heart disease , hypertrophic cardiomyopathy , Thrombolytic therapy within precede 24 hour Receiving antiIIb/IIIa therapy Creatinine clearance &lt; 30 mL/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>